Mazdutide

10mg · Lyophilized Powder · ~4,200 Da

$115.00 CAD

Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor (GCGR) co-agonist developed by Innovent Biologics, studied for its combined effects on energy balance through complementary pathways. While GLP-1 agonism reduces appetite and improves glucose homeostasis, GCGR activation increases hepatic glucose output and thermogenesis — together producing a distinct metabolic profile from pure GLP-1 agents. Phase 2 and Phase 3 GLORY trial data demonstrate significant weight reduction and glycaemic improvement in subjects with obesity and type 2 diabetes.

Research Applications

•Dual GLP-1/GCGR receptor co-agonism for metabolic modulation

•Body weight reduction through combined appetite and thermogenesis effects

•Hepatic glucose output modulation in metabolic research protocols

•Glycaemic control improvement in type 2 diabetes research models

•Comparative metabolic profiling versus single-agonist GLP-1 compounds

•Energy expenditure and adipose tissue research

VIAL10 mg

PURITY≥99% (HPLC)

FORMLyophilized powder

STORAGE-20°C lyophilized / 2-8°C reconstituted

RECON2.0 mL BAC water

USEResearch only

VIEW DOSING PROTOCOL →

All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.